Oncology
Astellas and Cullgen enter into $1.9bn strategic collaboration to progress protein degraders
June 15, 2023Research and Development Astellas, Cullgen, Oncology, protein degraders
Japanese pharmaceutical company Astellas and US-based clinical-stage biopharmaceutical company Cullgen have announced that they have entered into a strategic research …
Kymera Therapeutics reports positive data in cancer drug trials
June 14, 2023Research and Development Cancer, Kymera Therapeutics, Oncology, autoimmune diseases, clinical trials, inflammatory diseases
US clinical-stage biopharmaceutical company Kymera Therapeutics has shared new data regarding its oncology programmes KT-333 and KT-413, highlighting their robust dose-dependent …
AstraZeneca’s breast cancer drug given Priority Review by FDA
June 13, 2023Business Services AstraZeneca, FDA, Oncology, breast cancer
UK-based pharmaceutical company AstraZeneca has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application …
AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment
June 9, 2023Research and Development AstraZeneca, Cancer, MSD, NICE, Oncology, lynparza, pharma
UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) posted a positive recommendation …
GRAIL and University of Oxford showcase first prospective study results for multi-cancer early detection test
June 6, 2023Research and Development Cancer, GRAIL, Oncology, University of Oxford, cancer testing
US-based healthcare company GRAIL and the University of Oxford, UK, have announced encouraging first prospective study results at the American …
ISA Pharmaceuticals highlights positive clinical data at ASCO
June 6, 2023Research and Development ASCO, Cancer, HPV, ISA Pharmaceuticals, Oncology
Clinical stage biotechnology company ISA Pharmaceuticals has announced positive phase 1 data at the American Society of Clinical Oncology (ASCO) …
GSK receives FDA file acceptance for Jemperli plus chemotherapy for treating endometrial cancer
June 6, 2023Research and Development GSK, Jemperli, Oncology, endometrial cancer, oncology
GSK has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …
Allogene Therapeutics shares updated ALLO-501/501A phase 1 data in large B-cell lymphoma at ASCO annual meeting
June 5, 2023Research and Development Allogene, LBCL, Oncology, lymphoma, oncology
Allogene Therapeutics has shared updated data from the phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory (r/r) large …
BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910
June 2, 2023Research and Development BioInvent, NSCLC, Oncology, monoclonal antibody
Swedish clinical stage biotech company BioInvent has announced that it has received Investigational New Drug (IND) approval for its monoclonal …
Lonza to acquire Synaffix to strengthen ADC development
June 1, 2023Medical Communications ADC, Lonza, Oncology, Synaffix, drug development
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company …
Bristol Myers Squibb’s NDA accepted by FDA
May 31, 2023Medical Communications FDA, NDA, NSCLC, Oncology, bristol myers squibb
Global pharmaceutical company Bristol Myers Squibb (BMS) has announced that its New Drug Application (NDA) has been accepted by the …
BioInvent and Transgene announce positive phase 1a solid tumour trial data
May 25, 2023Research and Development BioInvent, Oncology, Transgene, clinical trials, oncology, tumours
Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from a trial studying BT-001 for …
AstraZeneca shares oncology data at ASCO 2023
May 25, 2023Medical Communications ASCO, AstraZeneca, Cancer, Oncology, oncology
AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting on …
FDA announces acceptance and priority review of NDA for LUMISIGHT imagining agent for breast cancer
May 23, 2023Research and Development FDA, Lumicell, Oncology, breast cancer, oncology
Lumicell has announced that the US Food and Drug Administration (FDA) has accepted and granted priority review for the New …
Oncimmune Holdings sells businesses to Freenome in £13m deal
May 22, 2023Sales and Marketing Freenome, Oncimmune Holdings, Oncology, acquisition
UK-based life sciences and immunodiagnostics firm Oncimmune Holdings has announced that it has sold its Oncimmune Limited and Oncimmune Europe …
Latest content
FibroFind appoints Lee Borthwick as CEO
